Brian O Mahony/X
Jul 21, 2025, 13:10
What’s Slowing Down Gene Therapy Uptake in Hemophilia? Brian O’Mahony Explains the Real-World Barriers
Brian O’Mahony, CEO of Irish Haemophilia Society,former President of WFH and EHC, highlights several key challenges that are currently limiting the widespread adoption of gene therapy in hemophilia in his recently shared post on X:
“Uncertainty about outcomes and side effects,
Complex reimbursement systems,
Availability of other excellent therapies,
Lack of center preparedness and resources.”
Despite the promise of a functional cure, real-world barriers continue to delay broader implementation.
Want to understand the future of gene therapy and how to overcome systemic obstacles?
Find the latest updates and expert commentary — only on Hemostasis Today, your trusted source for frontline academic insights in hematology and hemostasis.
-
Dec 8, 2025, 11:23Jorge Di Paola and Diane Krause Take Their Awards at ASH25
-
Dec 8, 2025, 11:08Andreas Tiede: This Will Change Hematology Forever
-
Dec 8, 2025, 09:39Asfand Yar Cheema Honored with Abstract Achievement Awards at ASH25
-
Dec 8, 2025, 09:27Ana Rita Rodrigues on the Impact of Post-Stroke Dysphagia
-
Dec 8, 2025, 09:19Sanam Loghavi and Shannon McWeeney at Joint Session on AI nad Hematology at ASH25
-
Dec 7, 2025, 18:43ASH25 Day 2: Don’t Miss The Highlights
-
Dec 7, 2025, 18:05Heghine Khachatryan Highlights a Patient-Friendly Breakthrough: Finger-Prick Micro-Sampling for Platelet Function
-
Dec 7, 2025, 17:01Abdul Mannan: How Do You Manage a Major Surgery When Blood Transfusion is Impossible?
-
Dec 7, 2025, 16:51Ahmed Bahi on Lina Merghani’s Critique of Early Withdrawal of Aspirin after PCI